PURPOSE: The transporter associated with antigen processing (TAP) is essential in assembling MHC-I proteins. Human papillomavirus (HPV) evades immune recognition by decreasing class I MHC cell surface expression through down-regulation of TAP1 levels. Consistent with heterogeneity in MHC expression is the individual variability in clearing detectable HPV infections. Genetic polymorphisms in TAP genes may affect protein structure, function, and the ability to clear HPV infection. EXPERIMENTAL DESIGN: Case-control study of women with cervical intraepithelial neoplasia (CIN) II or III (n = 114) and women without high-grade CIN (n = 366). Five nonsynonymous single nucleotide polymorphisms (SNP) in TAP1 and TAP2 were genotyped using DNA collected in cervicovaginal lavage samples using microsphere array technology (Luminex xMAP). HPV typing was done using a PCR-based system with MY09/MY11 primers. TAP1 and TAP2 SNPs were validated by direct sequencing. RESULTS: Differences in allele distribution between women with high-grade cervical neoplasia and women without was seen for TAP1 I333V (P = 0.02) and TAP1 D637G (P = 0.01). The odds ratios (OR) for CIN III were significantly lower among carriers of the TAP1 I333V polymorphism (OR, 0.28; 95% confidence interval, 0.1-0.8), and TAP1 D637G polymorphism (OR, 0.27; 95% confidence interval, 0.1-0.7). These associations remained significant even after restricting the evaluation to women who were positive for high-risk HPV types. CONCLUSIONS: In addition to the down-regulation of MHC-1 by oncogenic HPV, HPV pathogenesis might be facilitated by polymorphisms in the TAP proteins. Identifying TAP polymorphisms may potentially be used to identify women less susceptible to progression to high-grade CIN and cervical cancer.
PURPOSE: The transporter associated with antigen processing (TAP) is essential in assembling MHC-I proteins. Human papillomavirus (HPV) evades immune recognition by decreasing class I MHC cell surface expression through down-regulation of TAP1 levels. Consistent with heterogeneity in MHC expression is the individual variability in clearing detectable HPV infections. Genetic polymorphisms in TAP genes may affect protein structure, function, and the ability to clear HPV infection. EXPERIMENTAL DESIGN: Case-control study of women with cervical intraepithelial neoplasia (CIN) II or III (n = 114) and women without high-grade CIN (n = 366). Five nonsynonymous single nucleotide polymorphisms (SNP) in TAP1 and TAP2 were genotyped using DNA collected in cervicovaginal lavage samples using microsphere array technology (Luminex xMAP). HPV typing was done using a PCR-based system with MY09/MY11 primers. TAP1 and TAP2 SNPs were validated by direct sequencing. RESULTS: Differences in allele distribution between women with high-grade cervical neoplasia and women without was seen for TAP1I333V (P = 0.02) and TAP1D637G (P = 0.01). The odds ratios (OR) for CIN III were significantly lower among carriers of the TAP1I333V polymorphism (OR, 0.28; 95% confidence interval, 0.1-0.8), and TAP1D637G polymorphism (OR, 0.27; 95% confidence interval, 0.1-0.7). These associations remained significant even after restricting the evaluation to women who were positive for high-risk HPV types. CONCLUSIONS: In addition to the down-regulation of MHC-1 by oncogenic HPV, HPV pathogenesis might be facilitated by polymorphisms in the TAP proteins. Identifying TAP polymorphisms may potentially be used to identify women less susceptible to progression to high-grade CIN and cervical cancer.
Authors: H M Bauer; A Hildesheim; M H Schiffman; A G Glass; B B Rush; D R Scott; D M Cadell; R J Kurman; M M Manos Journal: Sex Transm Dis Date: 1993 Sep-Oct Impact factor: 2.830
Authors: R D Burk; P Kelly; J Feldman; J Bromberg; S H Vermund; J A DeHovitz; S H Landesman Journal: Sex Transm Dis Date: 1996 Jul-Aug Impact factor: 2.830
Authors: Akash M Mehta; Ekaterina S Jordanova; Tom van Wezel; Hae-Won Uh; Willem E Corver; Kitty M C Kwappenberg; Willem Verduijn; Gemma G Kenter; Sjoerd H van der Burg; Gert J Fleuren Journal: Genes Chromosomes Cancer Date: 2007-06 Impact factor: 5.006
Authors: V R Bonagura; F P Siegal; A L Abramson; F Santiago-Schwarz; M E O'Reilly; K Shah; D Drake; B M Steinberg Journal: Clin Diagn Lab Immunol Date: 1994-05
Authors: Carolyn E Banister; Amy R Messersmith; Bo Cai; Lisa B Spiryda; Saundra H Glover; Lucia Pirisi; Kim E Creek Journal: J Infect Dis Date: 2014-07-15 Impact factor: 5.226
Authors: Clara Bodelon; Margaret M Madeleine; Lisa G Johnson; Qin Du; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz Journal: Gynecol Oncol Date: 2011-11-28 Impact factor: 5.482
Authors: Charles T Spencer; Srdjan M Dragovic; Stephanie B Conant; Jennifer J Gray; Mu Zheng; Parimal Samir; Xinnan Niu; Magdalini Moutaftsi; Luc Van Kaer; Alessandro Sette; Andrew J Link; Sebastian Joyce Journal: Eur J Immunol Date: 2013-03-05 Impact factor: 5.532
Authors: Andrzej Wiśniewski; Maciej Sobczyński; Konrad Pawełczyk; Irena Porębska; Monika Jasek; Marta Wagner; Wanda Niepiekło-Miniewska; Aneta Kowal; Joanna Dubis; Natalia Jędruchniewicz; Piotr Kuśnierczyk Journal: Front Immunol Date: 2021-05-31 Impact factor: 7.561